These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Growing recognition of the role for rare missense substitutions in breast cancer susceptibility. Tavtigian SV; Chenevix-Trench G Biomark Med; 2014; 8(4):589-603. PubMed ID: 24796624 [TBL] [Abstract][Full Text] [Related]
25. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer. Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968 [TBL] [Abstract][Full Text] [Related]
26. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women. Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877 [TBL] [Abstract][Full Text] [Related]
27. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. Damiola F; Pertesi M; Oliver J; Le Calvez-Kelm F; Voegele C; Young EL; Robinot N; Forey N; Durand G; Vallée MP; Tao K; Roane TC; Williams GJ; Hopper JL; Southey MC; Andrulis IL; John EM; Goldgar DE; Lesueur F; Tavtigian SV Breast Cancer Res; 2014 Jun; 16(3):R58. PubMed ID: 24894818 [TBL] [Abstract][Full Text] [Related]
28. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182 [TBL] [Abstract][Full Text] [Related]
29. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2. Kraus C; Hoyer J; Vasileiou G; Wunderle M; Lux MP; Fasching PA; Krumbiegel M; Uebe S; Reuter M; Beckmann MW; Reis A Int J Cancer; 2017 Jan; 140(1):95-102. PubMed ID: 27616075 [TBL] [Abstract][Full Text] [Related]
30. Ten genes for inherited breast cancer. Walsh T; King MC Cancer Cell; 2007 Feb; 11(2):103-5. PubMed ID: 17292821 [TBL] [Abstract][Full Text] [Related]
31. Germline mutations in a DNA repair pathway are associated with familial colorectal cancer. Xu P; Sun D; Gao Y; Jiang Y; Zhong M; Zhao G; Chen J; Wang Z; Liu Q; Hong J; Chen H; Chen YX; Fang JY JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549727 [TBL] [Abstract][Full Text] [Related]
32. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Wong MW; Nordfors C; Mossman D; Pecenpetelovska G; Avery-Kiejda KA; Talseth-Palmer B; Bowden NA; Scott RJ Breast Cancer Res Treat; 2011 Jun; 127(3):853-9. PubMed ID: 21409391 [TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes. Singh K; Scalia J; Legare R; Quddus MR; Sung CJ Hum Pathol; 2024 Apr; 146():49-56. PubMed ID: 38608781 [TBL] [Abstract][Full Text] [Related]
34. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity. Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368 [TBL] [Abstract][Full Text] [Related]
35. Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. Fewings E; Larionov A; Redman J; Goldgraben MA; Scarth J; Richardson S; Brewer C; Davidson R; Ellis I; Evans DG; Halliday D; Izatt L; Marks P; McConnell V; Verbist L; Mayes R; Clark GR; Hadfield J; Chin SF; Teixeira MR; Giger OT; Hardwick R; di Pietro M; O'Donovan M; Pharoah P; Caldas C; Fitzgerald RC; Tischkowitz M Lancet Gastroenterol Hepatol; 2018 Jul; 3(7):489-498. PubMed ID: 29706558 [TBL] [Abstract][Full Text] [Related]
36. Martín-Morales L; Garre P; Lorca V; Cazorla M; Llovet P; Bando I; García-Barberan V; González-Morales ML; Esteban-Jurado C; de la Hoya M; Castellví-Bel S; Caldés T Cancer Prev Res (Phila); 2021 Feb; 14(2):185-194. PubMed ID: 33115781 [TBL] [Abstract][Full Text] [Related]
37. Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines. Ohmoto A; Morizane C; Kubo E; Takai E; Hosoi H; Sakamoto Y; Kondo S; Ueno H; Shimada K; Yachida S; Okusaka T J Gastroenterol; 2018 Oct; 53(10):1159-1167. PubMed ID: 29667044 [TBL] [Abstract][Full Text] [Related]
38. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations. Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916 [TBL] [Abstract][Full Text] [Related]
39. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis. Alter BP; Best AF Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392 [TBL] [Abstract][Full Text] [Related]
40. Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan. Rashid MU; Khan FA; Muhammad N; Loya A; Hamann U Cancer Res Treat; 2019 Jul; 51(3):992-1000. PubMed ID: 30309218 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]